These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 27635694)

  • 1. Poisoning due to MDMB-CHMICA, a synthetic cannabinoid receptor agonist.
    Meyyappan C; Ford L; Vale A
    Clin Toxicol (Phila); 2017 Feb; 55(2):151-152. PubMed ID: 27635694
    [No Abstract]   [Full Text] [Related]  

  • 2. Analysis and clinical findings of cases positive for the novel synthetic cannabinoid receptor agonist MDMB-CHMICA.
    Seywright A; Torrance HJ; Wylie FM; McKeown DA; Lowe DJ; Stevenson R
    Clin Toxicol (Phila); 2016 Sep; 54(8):632-7. PubMed ID: 27213960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analytically Confirmed Intoxications Involving MDMB-CHMICA from the STRIDA Project.
    Bäckberg M; Tworek L; Beck O; Helander A
    J Med Toxicol; 2017 Mar; 13(1):52-60. PubMed ID: 27638057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatal intoxication with synthetic cannabinoid MDMB-CHMICA.
    Adamowicz P
    Forensic Sci Int; 2016 Apr; 261():e5-10. PubMed ID: 26934903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study.
    Hill SL; Najafi J; Dunn M; Acheampong P; Kamour A; Grundlingh J; Blain PG; Thomas SH
    Clin Toxicol (Phila); 2016 Sep; 54(8):638-43. PubMed ID: 27251903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA.
    Hermanns-Clausen M; Müller D; Kithinji J; Angerer V; Franz F; Eyer F; Neurath H; Liebetrau G; Auwärter V
    Clin Toxicol (Phila); 2018 Jun; 56(6):404-411. PubMed ID: 29072524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDMB-CHMICA: Availability, Patterns of Use, and Toxicity Associated With This Novel Psychoactive Substance.
    Haden M; Archer JR; Dargan PI; Wood DM
    Subst Use Misuse; 2017 Jan; 52(2):223-232. PubMed ID: 27759479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sudden Cardiac Death Following Use of the Synthetic Cannabinoid MDMB-CHMICA.
    Westin AA; Frost J; Brede WR; Gundersen PO; Einvik S; Aarset H; Slørdal L
    J Anal Toxicol; 2016; 40(1):86-7. PubMed ID: 26353925
    [No Abstract]   [Full Text] [Related]  

  • 9. The impact of Australian legislative changes on synthetic cannabinoid exposures reported to the New South Wales Poisons Information Centre.
    Cairns R; Brown JA; Gunja N; Buckley NA
    Int J Drug Policy; 2017 May; 43():74-82. PubMed ID: 28343112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute Toxicity Associated with Use of 5F-Derivations of Synthetic Cannabinoid Receptor Agonists with Analytical Confirmation.
    Abouchedid R; Ho JH; Hudson S; Dines A; Archer JR; Wood DM; Dargan PI
    J Med Toxicol; 2016 Dec; 12(4):396-401. PubMed ID: 27456262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The "new" marijuana.
    Wells DL; Ott CA
    Ann Pharmacother; 2011 Mar; 45(3):414-7. PubMed ID: 21325097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of the Psychoactive Substances Act 2016 on the online availability of MDMB-CHMICA.
    Haden M; Wood DM; Dargan PI
    QJM; 2017 Oct; 110(10):619-622. PubMed ID: 28339898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MAM-2201 (analytically confirmed) intoxication after "Synthacaine" consumption.
    Lonati D; Buscaglia E; Papa P; Valli A; Coccini T; Giampreti A; Petrolini VM; Vecchio S; Serpelloni G; Locatelli CA
    Ann Emerg Med; 2014 Dec; 64(6):629-32. PubMed ID: 24530110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of changes in UK classification of the synthetic cannabinoid receptor agonists in 'Spice'.
    Dargan PI; Hudson S; Ramsey J; Wood DM
    Int J Drug Policy; 2011 Jul; 22(4):274-7. PubMed ID: 21482092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute intoxication of four individuals following use of the synthetic cannabinoid MAB-CHMINACA.
    Adamowicz P; Gieroń J
    Clin Toxicol (Phila); 2016 Sep; 54(8):650-4. PubMed ID: 27227269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Schedules of Controlled Substances: Temporary Placement of Six Synthetic Cannabinoids (5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA) into Schedule I. Temporary Scheduling Order.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2017 Apr; 82(67):17119-24. PubMed ID: 28425681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychiatric sequelae of Spice, K2, and synthetic cannabinoid receptor agonists.
    Benford DM; Caplan JP
    Psychosomatics; 2011; 52(3):295. PubMed ID: 21565605
    [No Abstract]   [Full Text] [Related]  

  • 18. The rise in K2 use with varying clinical symptoms and the potential for ED crowding.
    Roy AA; DeNonno L; Becerra I; Chirurgi R; McCorkell P; Hassen GW
    Am J Emerg Med; 2015 Apr; 33(4):582. PubMed ID: 25662800
    [No Abstract]   [Full Text] [Related]  

  • 19. A teenager with agitation: higher than she should have climbed.
    Vearrier D; Osterhoudt KC
    Pediatr Emerg Care; 2010 Jun; 26(6):462-5. PubMed ID: 20531137
    [No Abstract]   [Full Text] [Related]  

  • 20. Cumyl-PEGACLONE: A comparatively safe new synthetic cannabinoid receptor agonist entering the NPS market?
    Halter S; Angerer V; Röhrich J; Groth O; Roider G; Hermanns-Clausen M; Auwärter V
    Drug Test Anal; 2019 Feb; 11(2):347-349. PubMed ID: 30468574
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.